KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

J Clin Oncol · 2026-Feb-10 · PMID 41505697

Panel B提取完成待 EXE 对齐验证

OS

FIG A2. Kaplan-Meier estimates of RFS (A) and postresection OS (B) in patients who underwent secondary R0 surgery, according to treatment groups. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. FOLFOX, fluorouracil, leucovorin, oxaliplatin; HR, hazard ratio; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; NE, not estimable; OS, overall survival; R0, no residual tumor; RFS, relapse-free survival.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-23T16:59:45+00:00